Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

February 05, 2013; 80 (6) Article

Rivastigmine for HIV-associated neurocognitive disorders

A randomized crossover pilot study

Samanta Simioni, Matthias Cavassini, Jean-Marie Annoni, Mélanie Métral, Katia Iglesias, Aline Rimbault Abraham, Samantha Jilek, Alexandra Calmy, Hubertus Müller, Aurélie Fayet-Mello, Ezio Giacobini, Bernard Hirschel, Renaud A. Du Pasquier
First published January 23, 2013, DOI: https://doi.org/10.1212/WNL.0b013e3182815497
Samanta Simioni
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Cavassini
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Marie Annoni
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mélanie Métral
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katia Iglesias
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aline Rimbault Abraham
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samantha Jilek
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Calmy
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hubertus Müller
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurélie Fayet-Mello
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ezio Giacobini
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Hirschel
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renaud A. Du Pasquier
From the Departments of Neurology (S.S., R.A.D.), Infectious Diseases (M.C.), Clinical Research Center (K.I.), Clinical Pharmacology (A.F.-M.), and Immunology and Allergy (S.J., R.A.D.), CHUV, Lausanne; University and Hospital of Fribourg (J.-M.A.), Fribourg; and Departments of Neurology (M.M., A.R.A., H.M.), HIV/AIDS (A.C., B.H.), and Rehabilitation and Geriatrics (E.G.), HUG, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Rivastigmine for HIV-associated neurocognitive disorders
A randomized crossover pilot study
Samanta Simioni, Matthias Cavassini, Jean-Marie Annoni, Mélanie Métral, Katia Iglesias, Aline Rimbault Abraham, Samantha Jilek, Alexandra Calmy, Hubertus Müller, Aurélie Fayet-Mello, Ezio Giacobini, Bernard Hirschel, Renaud A. Du Pasquier
Neurology Feb 2013, 80 (6) 553-560; DOI: 10.1212/WNL.0b013e3182815497

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
320

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.

Methods: Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by placebo (20 weeks) or placebo followed by rivastigmine. Efficacy endpoints were improvement on rivastigmine in the Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS-Cog) and individual neuropsychological scores of information processing speed, attention/working memory, executive functioning, and motor skills. Measures of safety included frequency and nature of adverse events and abnormalities on laboratory tests and on plasma concentrations of antiretroviral drugs. Analyses of variance with repeated measures were computed to look for treatment effects.

Results: There was no change on the primary outcome ADAS-Cog on drug. For secondary outcomes, processing speed improved on rivastigmine (Trail Making Test A: F1,13 = 5.57, p = 0.03). One measure of executive functioning just failed to reach significance (CANTAB Spatial Working Memory [strategy]: F1,13 = 3.94, p = 0.069). No other change was observed. Adverse events were frequent, but not different from those observed in other populations treated with rivastigmine. No safety issues were recorded.

Conclusions: Rivastigmine in aviremic HIV+ patients with HAND seemed to improve psychomotor speed. A larger trial with the better tolerated transdermal form of rivastigmine is warranted.

Classification of evidence: This study provides Class III evidence that rivastigmine is ineffective for improving ADAS-Cog scores, but is effective in improving some secondary outcome measures in aviremic HIV+ patients with HAND.

GLOSSARY

AD=
Alzheimer disease;
ADAS-Cog=
Alzheimer's Disease Assessment Scale–Cognitive subscale;
CANTAB=
Cambridge Neuropsychological Test Automated Battery;
cART=
combined antiretroviral therapy;
ChEI=
cholinesterase inhibitors;
DSM-IV=
Diagnostic and Statistical Manual of Mental Disorders, 4th edition;
HAD=
HIV-associated dementia;
HAD-A=
Hospital Anxiety and Depression scale–anxiety;
HAD-D=
Hospital Anxiety and Depression scale–depression;
HAND=
HIV-associated neurocognitive disorders;
HDS=
HIV Dementia Scale;
LP=
lumbar puncture;
MND=
mild neurocognitive disorders;
MOS-HIV=
Medical Outcome Study HIV Health Survey;
NNRTI=
non-nucleoside reverse transcriptase inhibitors;
PD=
Parkinson disease;
QoL=
quality of life;
SWM=
Spatial Working Memory;
TDM=
therapeutic drug monitoring;
TMT=
Trail Making Test

Footnotes

  • Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Received May 25, 2012.
  • Accepted September 27, 2012.
  • © 2013 American Academy of Neurology
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • METHODS
    • RESULTS
    • DISCUSSION
    • AUTHOR CONTRIBUTIONS
    • STUDY FUNDING
    • DISCLOSURE
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis

Dr. Robert Pitceathly and Dr. William Macken

► Watch

Related Articles

  • Warfarin treatment and thrombolysisHow to persuade procrastinators?
  • tPA and warfarinTime to move forward
  • Neighborhood socioeconomic status and stroke mortalityDisentangling individual and area effects
  • The border-land of epilepsy—Revisited
  • Diagnostic shifts in ALS?From clinical specter to imaging spectra
  • Biomarkers for PDHow can we approach complexity?
  • Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS
  • Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease

Topics Discussed

  • Clinical trials Randomized controlled (CONSORT agreement)
  • HIV

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Articles
    Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
    John C. Morris, Pamela A. Cyrus, John Orazem et al.
    Neurology, May 01, 1998
  • Articles
    Alzheimer's Disease Neuroimaging Initiative (ADNI)
    Clinical characterization
    R. C. Petersen, P. S. Aisen, L. A. Beckett et al.
    Neurology, December 30, 2009
  • Article
    Randomized controlled trials in mild cognitive impairment
    Sources of variability
    Ronald C. Petersen, Ronald G. Thomas, Paul S. Aisen et al.
    Neurology, April 05, 2017
  • Articles
    A phase II trial of huperzine A in mild to moderate Alzheimer disease
    M.S. Rafii, S. Walsh, J.T. Little et al.
    Neurology, April 18, 2011
Neurology: 100 (12)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise